Molecular determinants and therapeutic potential of focal ectopic activity: more than meets the Iti

Jordi Heijman¹, Dobromir Dobrev^{2

3

4}

Affiliations

¹ Department of Cardiology, Cardiovascular Research Institute Maastricht, Faculty of Health, Medicine, and Life Sciences, Maastricht University, Maastricht, The Netherlands.
² Institute of Pharmacology, West German Heart and Vascular Center, University of Duisburg-Essen, Essen, Germany.
³ Department of Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, TX, USA.
⁴ Departments of Medicine and Research Center, Montreal Heart Institute and Université de Montréal, Montréal, Canada.

Editorial

Jordi Heijman et al. Eur Heart J. 2022.

. 2022 Oct 21;43(40):4208-4210.

doi: 10.1093/eurheartj/ehac357.

Jordi Heijman¹, Dobromir Dobrev^{2

3

4}

¹ Department of Cardiology, Cardiovascular Research Institute Maastricht, Faculty of Health, Medicine, and Life Sciences, Maastricht University, Maastricht, The Netherlands.
² Institute of Pharmacology, West German Heart and Vascular Center, University of Duisburg-Essen, Essen, Germany.
³ Department of Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, TX, USA.
⁴ Departments of Medicine and Research Center, Montreal Heart Institute and Université de Montréal, Montréal, Canada.

No abstract available

Conflict of interest statement

Conflict of interest: None declared.

TRPM4 inhibition by meclofenamate suppresses Ca2+-dependent triggered arrhythmias.
Vandewiele F, Pironet A, Jacobs G, Kecskés M, Wegener J, Kerselaers S, Hendrikx L, Verelst J, Philippaert K, Oosterlinck W, Segal A, Van Den Broeck E, Pinto S, Priori SG, Lehnart SE, Nilius B, Voets T, Vennekens R. Vandewiele F, et al. Eur Heart J. 2022 Oct 21;43(40):4195-4207. doi: 10.1093/eurheartj/ehac354. Eur Heart J. 2022. PMID: 35822895